Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) after failed hematopoietic autologous stem cell transplantation. At 5 years, the overall patient population (N = 102) had an estim...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood Jg. 128; H. 12; S. 1562
Hauptverfasser:	Chen, Robert, Gopal, Ajay K, Smith, Scott E, Ansell, Stephen M, Rosenblatt, Joseph D, Savage, Kerry J, Connors, Joseph M, Engert, Andreas, Larsen, Emily K, Huebner, Dirk, Fong, Abraham, Younes, Anas
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 22.09.2016
Schlagworte:	Adult Brentuximab Vedotin Female Hodgkin Disease - drug therapy Hodgkin Disease - mortality Hodgkin Disease - pathology Humans Immunoconjugates - therapeutic use Male Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Staging Prognosis Remission Induction Salvage Therapy Survival Rate
ISSN:	1528-0020, 1528-0020
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!